Ion Beam Applications SA (IOBCF) Q4 2024 Earnings Call Transcript
https://seekingalpha.com/article/4769331-ion-beam-applications-sa-iobcf-q4-2024-earnings-call-transcript?source=feed_sector_transcripts
Mar 20, 2025 -
0
Ionis Pharma Beats Expectations for Q4
https://www.fool.com/data-news/2025/02/19/ionis-pharma-beats-expectations-for-q4/?source=iedfolrf0000001
Feb 19, 2025 - The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.
0
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
https://www.zacks.com/stock/news/2332301/biogen-s-phase-ii-iii-sma-study-for-higher-spinraza-dose-meets-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332301
Sep 05, 2024 - BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
0
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2331551/theravance-bio-tbph-up-2-2-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2331551
Sep 04, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-azn-after-q2-beat-view-raise?cid=CS-ZC-FT-analyst_blog|rank_focused-2316191
Aug 16, 2024 - AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
0
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-abbv-after-q2-beat-view-raise?cid=CS-ZC-FT-analyst_blog|rank_focused-2316191
Aug 05, 2024 - AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
0
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
https://www.zacks.com/stock/news/2305396/ionis-ions-completes-enrolment-for-rare-disease-drug-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2305396
Jul 19, 2024 - Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
0
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
https://www.zacks.com/stock/news/2293892/fda-accepts-ionis-ions-nda-for-rare-disease-drug-olezarsen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293892
Jun 26, 2024 - The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
0
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
https://www.zacks.com/stock/news/2290616/ionis-ions-expands-licensing-deal-with-otsuka-for-hae-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290616
Jun 19, 2024 - Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
0
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
https://www.zacks.com/stock/news/2282063/biogen-biib-gets-eu-approval-for-rare-disease-drug-qalsody?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282063
May 31, 2024 - Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
0
Page 1>